Science Explorer Back to mapMap
Discussion
Institution · Reata Pharmaceuticals (United States)

Most cited papers from Reata Pharmaceuticals (United States)

Reata Pharmaceuticals (United States)

What are the most cited papers from Reata Pharmaceuticals (United States)?

The most cited paper from Reata Pharmaceuticals (United States) is "Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases" (Antonio Cuadrado, Ana Isabel Rojo, Geoffrey Wells et al., 2019), with 1,477 citations. Next come "Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease" (1,021) and "Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes" (886).

Showing 50 of 60 papers. Every paper with more than 54 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases Antonio Cuadrado, Ana Isabel Rojo, Geoffrey Wells et al. · Nature Reviews Drug Discovery ReviewOpen access 4 Jan 2019 1,477
2 Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease Dick de Zeeuw, Tadao Akizawa, Paul Audhya et al. · New England Journal of Medicine Open access 9 Nov 2013 1,021
3 Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes Pablo E. Pérgola, Philip Raskin, Robert Daniel Toto et al. · New England Journal of Medicine Open access 24 Jun 2011 886
4 Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease Stacey Ruiz, Pablo E. Pérgola, Richard A. Zager et al. · Kidney International Open access 16 Jan 2013 722
5 Synthetic lethal screen identification of chemosensitizer loci in cancer cells Angelique W. Whitehurst, Brian O. Bodemann, Jessica Cardenas et al. · Nature Apr 2007 480
6 Diabetic Downregulation of Nrf2 Activity via ERK Contributes to Oxidative Stress–Induced Insulin Resistance in Cardiac Cells In Vitro and In Vivo Yi Tan, Tomonaga Ichikawa, Jinqing Li et al. · Diabetes Open access 21 Jan 2011 401
7 Safety and Efficacy of Omaveloxolone in Friedreich Ataxia ( MOXIe Study) David R. Lynch, Melanie P. Chin, Martin B. Delatycki et al. · Annals of Neurology Open access 17 Oct 2020 325
8 Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer Srinivas Nagaraj, Je-In Youn, Hannah Weber et al. · Clinical Cancer Research Open access 9 Mar 2010 280
9 A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas David S. Hong, Razelle Kurzrock, Jeffrey G. Supko et al. · Clinical Cancer Research Open access 26 May 2012 238
10 Triterpenoid CDDO-Me Blocks the NF-κB Pathway by Direct Inhibition of IKKβ on Cys-179 Rehan Ahmad, Deepak Bushan Raina, Colin J. Meyer et al. · Journal of Biological Chemistry Open access 25 Sep 2006 238
11 Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD Pablo E. Pérgola, Melissa Krauth, Jesse W. Huff et al. · American Journal of Nephrology Open access 2011 233
12 Proteomic analysis of protein changes developing in rat hippocampus after chronic antidepressant treatment: Implications for depressive disorders and future therapies Xavier Z. Khawaja, Jun Xu, Jinjun Liang et al. · Journal of Neuroscience Research 20 Jan 2004 208
13 Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia David R. Lynch et al. · Annals of Clinical and Translational Neurology Open access 10 Nov 2018 174
14 Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study Melanie P. Chin, George L. Bakris, Geoffrey A. Block et al. · American Journal of Nephrology Open access 2018 165
15 Dual Modes of Munc18-1/SNARE Interactions Are Coupled by Functionally Critical Binding to Syntaxin-1 N Terminus Mikhail V. Khvotchev, Irina Dulubova, Jianyuan Sun et al. · Journal of Neuroscience Open access 7 Nov 2007 165
16 Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl Melanie P. Chin, Danielle Wrolstad, George L. Bakris et al. · Journal of Cardiac Failure Open access 13 Oct 2014 164
17 The Slow Afterhyperpolarization in Hippocampal CA1 Neurons Covaries with Spatial Learning Ability in Aged Fisher 344 Rats Geoffrey C. Tombaugh, Wayne B. Rowe, Gregory M. Rose · Journal of Neuroscience Open access 9 Mar 2005 164
18 Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1 Qing Wu, Yanxia Wang, Martin Senitko et al. · American Journal of Physiology-Renal Physiology Open access 2 Feb 2011 157
19 Mechanisms Contributing to Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl Melanie P. Chin, Scott A. Reisman, George L. Bakris et al. · American Journal of Nephrology Open access 2014 151
20 Theta-Frequency Synaptic Potentiation in CA1In VitroDistinguishes Cognitively Impaired from Unimpaired Aged Fischer 344 Rats Geoffrey C. Tombaugh, Wayne B. Rowe, Ana Chow et al. · Journal of Neuroscience Open access 15 Nov 2002 145
21 Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed‐Start Analysis of the MOXIe Extension David R. Lynch, Melanie P. Chin, Sylvia Boesch et al. · Movement Disorders Open access 29 Nov 2022 125
22 Triterpenoid CDDO-Methyl Ester Inhibits the Janus-Activated Kinase-1 (JAK1)→Signal Transducer and Activator of Transcription-3 (STAT3) Pathway by Direct Inhibition of JAK1 and STAT3 Rehan Ahmad, Deepak Bushan Raina, Colin J. Meyer et al. · Cancer Research Open access 15 Apr 2008 119
23 Derivative of Bardoxolone Methyl, dh404, in an Inverse Dose-Dependent Manner Lessens Diabetes-Associated Atherosclerosis and Improves Diabetic Kidney Disease Sih Min Tan, Arpeeta Sharma, Nada Stefanovic et al. · Diabetes 17 Apr 2014 114
24 Injectable collagen as a pH-sensitive hydrogel Joel Rosenblatt, Brian M. Devereux, Donald G. Wallace · Biomaterials Oct 1994 114
25 Combination antioxidant therapy prevents epileptogenesis and modifies chronic epilepsy Tawfeeq Shekh‐Ahmad, Andreas Lieb, Stjepana Kovac et al. · Redox Biology Open access 19 Jul 2019 109
26 Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis Tej Kumar Pareek, Abdelmadjid Belkadi, Sashi Kesavapany et al. · Scientific Reports Open access 19 Dec 2011 105
27 RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity Brandon Probst, Treviño Isaac, McCauley Lyndsey et al. · PLoS ONE Open access 21 Apr 2015 103
28 Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney Scott A. Reisman, Glenn Matthew Chertow, Sudarshan Hebbar et al. · Journal of the American Society of Nephrology Open access 3 Aug 2012 101
29 Dihydro-CDDO-Trifluoroethyl Amide (dh404), a Novel Nrf2 Activator, Suppresses Oxidative Stress in Cardiomyocytes Tomonaga Ichikawa, Jinqing Li, Colin J. Meyer et al. · PLoS ONE Open access 18 Dec 2009 100
30 The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction Arpeeta Sharma, Luddwi Rizky, Nada Stefanovic et al. · Cardiovascular Diabetology Open access 2 Mar 2017 99
31 Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study Phoenix A. Ho et al. · Leukemia Open access 8 Apr 2010 97
32 Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON) Dick de Zeeuw, Tadao Akizawa, Rajiv Agarwal et al. · American Journal of Nephrology Open access 2013 94
33 A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD) Nigel David Toussaint et al. · Journal of the American Society of Nephrology Open access 11 Sep 2020 91
34 The spatiotemporal regulation of the Keap1–Nrf2 pathway and its importance in cellular bioenergetics Albena T. Dinkova‐Kostova, Liam Baird, Kira M. Holmström et al. · Biochemical Society Transactions Open access Aug 2015 86
35 A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD Geoffrey A. Block, Martha S. Block, Gerard Smits et al. · Journal of the American Society of Nephrology Open access 5 Jul 2019 83
36 Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405 Brandon Probst, McCauley Lyndsey, Treviño Isaac et al. · PLoS ONE Open access 24 Aug 2015 83
37 The novel triterpenoid RTA 408 protects human retinal pigment epithelial cells against H2O2-induced cell injury via NF-E2-related factor 2 (Nrf2) activation Xiaobin Liu, Keith W. Ward, Christy Xavier et al. · Redox Biology Open access 19 Dec 2015 81
38 Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats Han‐Ting Zhang, Ying Huang, Neesha U. Suvarna et al. · Psychopharmacology 25 Jan 2005 81
39 A Randomized, Placebo-Controlled Study Investigating the Nicotinic α7 Agonist, RG3487, for Cognitive Deficits in Schizophrenia Daniel Umbricht, Richard S.E. Keefe, Stephen A. Murray et al. · Neuropsychopharmacology Open access 27 Jan 2014 80
40 Topical Application of the Synthetic Triterpenoid RTA 408 Protects Mice from Radiation-Induced Dermatitis Scott A. Reisman, Chun‐Yue I. Lee, Colin J. Meyer et al. · Radiation Research Open access 10 Apr 2014 79
41 The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease Mohammad Amin Aminzadeh, Scott A. Reisman, Nosratola D. Vaziri et al. · Xenobiotica Open access 6 Nov 2013 78
42 Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic Retinopathy Devy Deliyanti, Saeed F. Alrashdi, Sih Min Tan et al. · Investigative Ophthalmology & Visual Science Open access 6 Feb 2018 73
43 Understanding the role of the cytoprotective transcription factor nuclear factor erythroid 2-related factor 2—lessons from evolution, the animal kingdom and rare progeroid syndromes Peter Stenvinkel, Colin J. Meyer, Geoffrey A. Block et al. · Nephrology Dialysis Transplantation Open access 17 May 2019 72
44 Characterization of novel small-molecule NRF2 activators: Structural and biochemical validation of stereospecific KEAP1 binding Carlos Huerta, Xin Jian Jiang, Treviño Isaac et al. · Biochimica et Biophysica Acta (BBA) - General Subjects Open access 28 Jul 2016 70
45 Age-related sex differences in spatial learning and basal forebrain cholinergic neurons in F344 rats Lone Veng, Ann Charlotte Granholm, Gregory M. Rose · Physiology & Behavior 22 Sep 2003 69
46 Serum Calcification Propensity and Clinical Events in CKD Joshua D. Bundy, Xuan Cai, Rupal C. Mehta et al. · Clinical Journal of the American Society of Nephrology Open access 28 Oct 2019 66
47 Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates Scott A. Reisman, Sarabjit Gahir, Chun‐Yue I. Lee et al. · Drug Design Development and Therapy Open access Apr 2019 66
48 Nrf2 regulates glucose uptake and metabolism in neurons and astrocytes Noemí Esteras, Thomas S. Blacker, Evgeny Zherebtsov et al. · Redox Biology Open access 14 Mar 2023 64
49 Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats Han‐Ting Zhang, Yu Zhao, Ying Huang et al. · Psychopharmacology 3 Apr 2006 64
50 Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin Scott A. Reisman, Chun‐Yue I. Lee, Colin J. Meyer et al. · Archives of Dermatological Research 21 Dec 2013 62

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.